Trial Profile
Post marketing study of Herceptin in patients with HER2-overexpressing metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Docetaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 16 Jun 2016 New trial record